Deniz Merde Özdemir

Deniz Merde Özdemir

Auto-generated profile, based on publicly available information

Deniz Merde Özdemir

Department of Endocrinology and Metabolism Adiyaman University Education and Research Hospital Adiyaman Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Experimental and Applied Medical Science
Verified
Journal Article
Open access
SMSezer Marki̇rt
Sezer Marki̇rt
EMErkan Marki̇rt
Erkan Marki̇rt
DÖDeniz Merde Özdemi̇r
Deniz Merde Özdemi̇r
YHYusuf HOSOGLU
Yusuf HOSOGLU
This case report presents a conservative management approach to a potentially hazardous complication, iatrogenic coronary artery dissection (ICAD), occurring during percutaneous coronary intervention (PCI). The patient, a 60-year-old woman with a history of chronic hypertension and type II diabetes mellitus, presented with non-ST-segment elevation myocardial infarction. During the PCI, an antegrade coronary dissection was observed, leading to the termination of the procedure. Post-procedure, the patient was managed conservatively with standard coronary artery disease treatment. Follow-up angiography showed complete healing of the dissection area, and no adverse cardiovascular events occurred during a 3-month follow-up period. This report highlights the importance of early diagnosis and careful management of ICAD. It stresses the need for further research into long-term outcomes and effectiveness of different treatment approaches for patients with ICAD.

4 August 2025 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Open access
YKYusuf Kayhan
Yusuf Kayhan
HKHakan Kaya
Hakan Kaya
VKVeysi Kavalci
Veysi Kavalci
SASabri Abuş
Sabri Abuş
KBKadir Biyikli
Kadir Biyikli
DÖDeniz Merde Özdemir
Deniz Merde Özdemir
Background: Dapagliflozin (DAPA), a sodium‐glucose cotransporter‐2 (SGLT2) inhibitor, may attenuate the risk of ventricular arrhythmia (VA) through its antiarrhythmic properties in patients with heart failure with reduced ejection fraction (HFrEF). The antiarrhythmic mechanisms of SGLT2 inhibitors are not fully known. Recently, the index of cardiac electrophysiological balance (ICEB) has been posited as a robust indicator for predicting VA risk. ICEB reflects the balance between ventricular depolarization and repolarization. This study was conducted to investigate the effects of DAPA treatment on ICEB in a cohort of patients with HFrEF.Methods: A total of 235 HFrEF patients undergoing DAPA treatment were enrolled in the study. Each participant underwent a comprehensive 12‐lead electrocardiography (ECG) assessment prior to treatment initiation and approximately 6 months posttreatment. ICEB values were compared before and after treatment.Results: The analysis revealed a statistically significant reduction in the QT interval (427.51 ± 13.87 vs. 347.75 ± 11.21 ms, p < 0.001), corrected QT interval (QTc) (458.34 ± 29.71 vs. 393.37 ± 13.21 ms, p < 0.001), T peak‐to‐end (Tp‐e) interval (85.41 ± 3.52 vs. 71.18 ± 3.16 ms, p < 0.001), Tp‐e/QTc ratio (0.186 ± 0.009 vs. 0.180 ± 0.003, p < 0.001), ICEB (4.59 ± 0.65 vs. 3.77 ± 0.15, p < 0.001), following approximately 6 months of DAPA treatment.Conclusion: In addition to ventricular repolarization distribution indices, the regression of the ICEB values after DAPA treatment in patients with HFrEF shows that DAPA treatment improves the balance between ventricular depolarization and repolarization and reduces the risk of VA in these patients.